This is a working overview of RP-HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-22. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
In contrast to organomagnesium compounds, organocalcium compounds are not similarly useful, with one major exception, calcium carbide, CaC2. This material, which has historic significance, is prepared by heating calcium oxide with carbon. According to X-ray crystallography, calcium carbide can be described as Ca2+ derivative of acetylide, C22-, although it is not a salt. Several million tons of calcium carbide are produced annually. Hydrolysis gives acetylene, which is used in welding and a chemical precursor. Reaction with nitrogen gas converts calcium carbide to calcium cyanamide. A dominant theme in molecular organocalcium chemistry is the large radius of calcium, which often leads to high coordination numbers. For example, dimethylcalcium appears to be a 3-dimensional polymer, whereas dimethylmagnesium is a linear polymer with tetrahedral Mg centers. Bulky ligands are often required to disfavor polymeric species. For example, calcium dicyclopentadienyl, Ca(C5H5)2 has a polymeric structure and thus is nonvolatile and insoluble in solvents. Replacing the C5H5 ligand with the bulkier C5(CH3)5 (pentamethylcyclopentadienyl) gives a soluble complex that sublimes and forms well-defined adducts with ethers. Organocalcium compounds tend to be more similar to organoytterbium compounds due to the similar ionic radii of Yb2+ (102 pm) and Ca2+ (100 pm). Organocalcium compounds have been well investigated. Some such complexes exhibit catalytic properties, although none have been commercialized.
Vildagliptin, sold under the brand name Galvus among others, is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. Bold textIt was approved by the European Medicines Agency (EMA) in 2007. The European Medicines Agency has also approved a combination of vildagliptin and metformin, vildagliptin/metformin (Eucreas by Novartis) as an oral treatment for type-2 diabetes. Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus.
On 9 August, Bildt compared Russia's reason for going to war with Georgia to Adolf Hitler's actions, "No state has the right to intervene militarily in the territory of another state simply because there are individuals there with a passport issued by that state or who are nationals of the state. Attempts to apply such a doctrine have plunged Europe into war in the past... And we have reason to remember how Hitler used this very doctrine little more than half a century ago to undermine and attack substantial parts of central Europe". A UN Security Council diplomat said: "Strategically, the Russians have been sending signals that they really wanted to flex their muscles, and they're upset about Kosovo." On 10 August, Russian human rights activist Sergei Kovalev called on the international community to condemn Russia's actions since Russia launched an aggression against Georgia on the pretext of defence of Russian citizens. The statement said that Russia was no longer a peacekeeper, but a party to the conflict. The statement was supported by Lev Ponomaryov and other Russian human rights activists. On 11 August, Ronald Asmus and Richard Holbrooke wrote that Georgia acted in response to provocation by Russian-backed separatists and Georgia did not want the war because it was already using soft power to attain its goals in South Ossetia.
== CGMP inspections == Regulatory agencies (including the FDA in the U.S. and regulatory agencies in many European nations) are authorized to conduct unannounced inspections, though some are scheduled. FDA routine domestic inspections are usually unannounced, but must be conducted according to 704(a) of the Food, Drug and Cosmetic Act (21 USCS § 374), which requires that they are performed at a "reasonable time". Courts have held that any time the firm is open for business is a reasonable time for an inspection.
Sources: en.wikipedia.org
=== Duration of action === The duration of action of a drug is the length of time that particular drug is effective. Duration of action is a function of several parameters including plasma half-life, the time to equilibrate between plasma and target compartments, and the off rate of the drug from its biological target.
== Genetics == Hemoglobin consists of protein subunits (globin molecules), which are polypeptides, long folded chains of specific amino acids which determine the protein's chemical properties and function. The amino acid sequence of any polypeptide is translated from a segment of DNA, the corresponding gene. There is more than one hemoglobin gene. In humans, hemoglobin A (the main form of hemoglobin in adults) is coded by genes HBA1, HBA2, and HBB. Alpha 1 and alpha 2 subunits are respectively coded by genes HBA1 and HBA2 close together on chromosome 16, while the beta subunit is coded by gene HBB on chromosome 11. The amino acid sequences of the globin subunits usually differ between species, with the difference growing with evolutionary distance. For example, the most common hemoglobin sequences in humans, bonobos and chimpanzees are completely identical, with exactly the same alpha and beta globin protein chains. Human and gorilla hemoglobin differ in one amino acid in both alpha and beta chains, and these differences grow larger between less closely related species. Mutations in the genes for hemoglobin can result in variants of hemoglobin within a single species, although one sequence is usually "most common" in each species. Many of these mutations cause no disease, but some cause a group of hereditary diseases called hemoglobinopathies. The best known hemoglobinopathy is sickle-cell disease, which was the first human disease whose mechanism was understood at the molecular level.
Gardner, who was vice president, had political ambitions and left the company when he was elected to the United States House of Representatives in 1966. The 1964 menu included hamburger for 15 cents, cheeseburgers for 20 cents, french fries for 10 cents, apple turnovers for 15 cents, milk for 12 cents, coffee for 10 cents, soft drinks for 10 cents, and milkshakes (chocolate, strawberry, vanilla) for 20 cents. Strawberry milkshakes were created from vanilla by addition of a berry syrup which had to be mixed with a spindle.
== Products and services == Schrödinger's computational platforms evaluate compounds in silico, with experimental accuracy on properties such as binding affinity and solubility. The company's products include molecular modeling programs in life science, and Materials Science, and an Enterprise Informatics Platform named LiveDesign, which is intended to facilitate communication among interdisciplinary research teams.
In 1899, he showed that negative electricity created by ultraviolet light landing on a metal (known now as the photoelectric effect) has the same mass-to-charge ratio as cathode rays; then he applied his previous method for determining the charge on ions to the negative electric particles created by ultraviolet light. By this combination he showed that electron's mass was 0.0014 times that of hydrogen ions. These "corpuscles" were so light yet carried so much charge that Thomson concluded they must be the basic particles of electricity, and for that reason other scientists decided that these "corpuscles" should instead be called electrons following an 1894 suggestion by George Johnstone Stoney for naming the basic unit of electrical charge. In 1904, Thomson published a paper describing a new model of the atom. Electrons reside within atoms, and they transplant themselves from one atom to the next in a chain in the action of an electrical current. When electrons do not flow, their negative charge logically must be balanced out by some source of positive charge within the atom so as to render the atom electrically neutral. Having no clue as to the source of this positive charge, Thomson tentatively proposed that the positive charge was everywhere in the atom, the atom being shaped like a sphere—this was the mathematically simplest model to fit the available evidence (or lack of it). The balance of electrostatic forces would distribute the electrons throughout this sphere in a more or less even manner.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.